Aronora Secures Investment From New York Blood Center
Summary
The funding will support team expansion, manufacturing, and regulatory activities as Aronora prepares for late-stage clinical development of their lead investigational products E-WE thrombin (AB002) and Gruticibart (AB023). Both drug candidates have completed phase 2a clinical trials, with compelling top-line data.Blood clots, the leading global cause of death, have long been a challenge for medical research, and treatments have lagged behind many other diseases. Their pioneering work led to the filing of the first patents on coagulation factor XI inhibition, giving rise to Aronoras innovative antibody, Gruticibart. Erik Tucker, Aronoras CEO, shared his journey, stating, "As a graduate student, I found our therapies worked better than currently available FDA-approved drugs, and had no bleeding issues. "NYBC Ventures Managing Director, Meg Wood, added, "Aronora is a trailblazing company at the forefront in developing a new generation of safer blood-thinning and clot-dissolving medications.